Colorized scanning electron micrographs of natural killer cells from a human donor (Images: NIH / Graphics: Shehla Shakoor, Endpoints News)
November 12, 2019 03:22 PM ESTUpdated November 13, 10:23 AM
R&D

Kiadis aban­dons lead PhI­II pro­gram, shifts fo­cus to nat­ur­al killer cells

Jason Mast

Editor

Kiadis Phar­ma an­nounced that it is shift­ing fo­cus to nat­ur­al killer cells — and is it­self killing off the long-run­ning but deeply trou­bled Phase III ATIR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times